Wildcat Capital Management sold 495,606 shares of UroGen Pharma for an estimated $6.79 million, fully exiting the stock by September 30. Top holdings post-sale include ULCC at $123.89 million and RLX at $16.88 million. UroGen Pharma’s shares have surged 113% in a year to $23.52.

UroGen Pharma specializes in innovative treatments for urothelial diseases and cancers. Leveraging hydrogel technology, the company focuses on unmet medical needs in urothelial oncology. With a robust pipeline and commercial products, UroGen Pharma stands out in the pharmaceutical sector.

Wildcat Capital’s full liquidation of UroGen Pharma amid a strong one-year run appears to be disciplined capital recycling rather than lack of confidence. Jelmyto remains a key product, with the pipeline targeting urothelial cancers. Biotech success can be volatile, prompting exits from patient capital.

Stock Advisor issues “Double Down” alerts for promising companies like Nvidia, Apple, and Netflix, offering significant returns over time. Join to access alerts for three exceptional companies. Don’t miss the chance to invest in potential market leaders. Stock Advisor returns as of December 22, 2025.

Read more at Yahoo Finance: Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally